Latest News

CTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONE 16-May-2013

BIONOMICS NOW MAY 2013 NEWSLETTER 06-May-2013

UPDATE ON BNC101 PRESENTED AT LEADING US ANTIBODY CONFERENCE 29-Apr-2013

MANUFACTURE OF BNC101 COMMENCES AT LONZA 23-Apr-2013

RIGHTS ISSUE CLOSURE AND SHORTFALL NOTICE 08-Apr-2013

BIONOMICS CEO NAMED BIOSPECTRUM ASIA PERSON OF THE YEAR 2013 18-Mar-2013

RIGHTS ISSUE - DESPATCH OF OFFER BOOKLET 18-Mar-2013

RIGHTS ISSUE - LETTER TO INELIGIBLE SHAREHOLDERS 18-Mar-2013

RIGHTS ISSUE - LETTER TO NOMINEES 18-Mar-2013

RIGHTS ISSUE - LETTER TO ELIGIBLE SHAREHOLDERS 05-Mar-2013

UNDERWRITTEN RIGHTS ISSUE TO RAISE $16.4 MILLION 04-Mar-2013

UNDERWRITTEN RIGHTS ISSUE OFFER BOOKLET 04-Mar-2013

BIONOMICS PROVIDES BNC101 UPDATE AT US CANCER STEM CELL CONFERENCE 11-Feb-2013

BNC375 ALZHEIMER'S DISEASE NEUROSCIENCE CONFERENCE POSTER 04-Feb-2013

BNC375 ALZHEIMER'S DISEASE DRUG CANDIDATE PRESENTED AT NEUROSCIENCE CONFERENCE 04-Feb-2013

BIONOMICS NOW FEBRUARY 2013 NEWSLETTER 01-Feb-2013

CASH FLOW REPORT FOR QUARTER ENDED 31 DECEMBER 2012 31-Jan-2013

BIONOMICS R&D TAX INCENTIVE FOR FY2012 15-Jan-2013

CEO UPDATE AND US INVESTOR PRESENTATION 09-Jan-2013

IRONWOOD BEGINS PHASE I TRIAL OF INVESTIGATIONAL IW-2143 ANXIETY DRUG IN US 21-Dec-2012

BIONOMICS NEW ALZHEIMER’S DRUG CANDIDATE 14-Dec-2012

INTERVIEW - DEBORAH RATHJEN AT AUSBIOTECH 2012 - PHARMATELEVISION 07-Dec-2012

CEO & MANAGING DIRECTOR AGM PRESENTATION 2012 14-Nov-2012

OUTGOING CHAIRMAN’S ADDRESS 14-Nov-2012

BNO LICENSEE, IRONWOOD SUBMITS IND APPLICATION FOR ANTI-ANXIETY DRUG 09-Nov-2012

IND SUBMISSION TO FDA FOR IW-2143 (BNC210) ANTI-ANXIETY DRUG CANDIDATE 08-Nov-2012

BIONOMICS ASX SMALL TO MID CAPS INVESTOR PRESENTATION 17-Oct-2012

ALPHA 7 PROGRAM TO BE SHOWCASED AT NEUROSCIENCE 2012 16-Oct-2012

BIONOMICS ANNUAL REPORT 2012 12-Oct-2012

RETIREMENT OF CHAIRMAN 11-Oct-2012

BIONOMICS APPOINTS GRAEME KAUFMAN NON-EXECUTIVE DIRECTOR 18-Sep-2012

BNO ACQUIRES US-BASED CANCER STEM CELL COMPANY PRESENTATION 17-Sep-2012

BIONOMICS ACQUIRES US-BASED CANCER STEM CELL COMPANY ECLIPSE THERAPEUTICS 17-Sep-2012

BIONOMICS KEY ADDITIONS TO EXECUTIVE TEAM 12-Sep-2012

BNC210 PARTNER IRONWOOD PHARMACEUTICALS RECEIVES US FDA APPROVAL FOR LINZESS™ 31-Aug-2012

BIONOMICS AUGUST 2012 INVESTOR PRESENTATION 17-Aug-2012

BIONOMICS SECURES KEY US PATENT FOR VASCULAR DISRUPTING AGENT BNC105 15-Aug-2012

BIONOMICS' 2011/2012 PRELIMINARY FINAL RESULTS 15-Aug-2012

FULL YEAR STATUTORY ACCOUNTS 15-Aug-2012

BIONOMICS NOW JULY 2012 NEWSLETTER 06-Jul-2012

OPEN BRIEFING - CEO ON Kv1.3 PROGRAM AND OUTLOOK 27-Jun-2012

US PATENT GRANTED FOR KV1.3 PROGRAM 26-Jun-2012

BIONOMICS TO EXPAND KV1.3 PROGRAM 15-Jun-2012

CEO BROADCAST - BNC105 TRIAL DATA 13-Jun-2012

BNC105 TRIAL DATA PRESENTED AT AMERICAN SOCIETY FOR CLINICAL ONCOLOGY (ASCO) 01-Jun-2012

BIONOMICS LAUNCHES BNC105 OVARIAN CANCER TRIAL 24-May-2012

LIFE SCIENCES CONFERENCE INVESTOR PRESENTATION 23-May-2012

JOINT BIONOMICS AND IRONWOOD ROADSHOW 18-Apr-2012

OPEN BRIEFING - CEO ON BNC105 OVARIAN CANCER TRIAL 03-Apr-2012

BNC105 OVARIAN CANCER PROGRESS 02-Apr-2012

BNC105 OVARIAN CANCER TRIAL APPROVED 23-Mar-2012

US & UK INVESTOR PRESENTATION 01-Mar-2012

BIONOMICS NOW FEBRUARY 2012 NEWSLETTER 21-Feb-2012

BIONOMICS TARGETS ALZHEIMER'S DISEASE 20-Feb-2012

BIONOMICS TARGETS ALZHEIMER’S DISEASE 16-Feb-2012

BNC105 RENAL CANCER TRIAL DATA PRESENTED AT ASCO-GU 03-Feb-2012

CASH FLOW REPORT FOR QUARTER ENDED 31 DECEMBER 2011 31-Jan-2012

CEO UPDATE AND US INVESTOR PRESENTATION 09-Jan-2012

CEO BIOTECH SHOWCASE PRESENTATION 2012 09-Jan-2012

IRONWOOD PHARMACEUTICALS AND BIONOMICS ANNOUNCE COLLABORATION, RESEARCH, AND LICENSE AGREEMENT 05-Jan-2012

BIONOMICS CEO DISCUSSES THE IRONWOOD COLLABORATION, RESEARCH, AND LICENSE AGREEMENT 05-Jan-2012

INVESTOR PRESENTATION - DECEMBER 2011 14-Dec-2011

BNC210 ANTI-ANXIETY CLINICAL DATA PRESENTED 15-Nov-2011

CEO ANNUAL GENERAL MEETING BROADCAST 11-Nov-2011

CHAIRMAN'S AGM PRESENTATION 2011 09-Nov-2011

CEO'S AGM PRESENTATION 2011 09-Nov-2011

ANNUAL GENERAL MEETING RESULTS 2011 09-Nov-2011

INVESTOR PRESENTATION - ASX SMALL TO MID CAPS 25-Oct-2011

BIONOMICS ANNUAL REPORT 2011 07-Oct-2011

NOTICE OF ANNUAL GENERAL MEETING / PROXY FORM 07-Oct-2011

OPEN BRIEFING - CEO ON BNC105 UPDATE AND OUTLOOK 05-Oct-2011

BNC105 RENAL CANCER TRIAL UPDATE 20-Sep-2011

LATEST BNC210 DATA PRESENTED AT MAJOR INTERNATIONAL CONFERENCE 01-Sep-2011

2011 STATUTORY ACCOUNTS 18-Aug-2011

BNO CEO BROADCAST - CLINICAL TRIALS REACH KEY MILESTONES 12-Aug-2011

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES 03-Aug-2011

BNO INVESTOR PRESENTATION - AUGUST 2011 03-Aug-2011

PHASE I BNC105 CLINICAL TRIAL PUBLISHED 23-Jun-2011

MERCK SERONO EXTENDS MULTIPLE SCLEROSIS COLLABORATION WITH BIONOMICS 09-Jun-2011

BNC105 RENAL CANCER TRIAL TO BE PRESENTED AT ASCO 03-Jun-2011

OPEN BRIEFING - OUTLOOK AND STRATEGIC FOCUS 25-May-2011

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY 16-May-2011

SUCCESSFUL REGISTER REPOSITIONING COMPLETE 13-May-2011

INDEPENDENT STUDY PROVIDES FURTHER VALIDATION OF BNC210 FOLLOWING RECENT SUCCESS OF PHASE Ib TRIALS 10-May-2011

BIONOMICS NOW MAY 2011 NEWSLETTER 06-May-2011

BNO SELLS THEBARTON PREMISES TO SUBSTANTIALLY BOOST CASH RESERVES 04-May-2011

BIONOMICS APRIL 2011 INVESTOR PRESENTATION 14-Apr-2011

BIONOMICS PRESENTS AT NEEDHAM HEALTHCARE CONFERENCE 06-Apr-2011

BOARDROOM RADIO BROADCAST - CEO ON ANTI-ANXIETY DRUG CLINICAL TRIALS RESULTS 05-Apr-2011

BNC105 DATA PRESENTED AT AACR CONFERENCE 01-Apr-2011

BIONOMICS ANTI-ANXIETY DRUG PHASE Ib CLINICAL TRIALS SUCCESSFUL RESULTS 30-Mar-2011

INVITATION TO TENDER FOR SHARES 30-Mar-2011

HALF YEARLY REPORT AND ACCOUNTS 11-Feb-2011

BNC105 DATA PRESENTED AT LORNE CANCER CONFERENCE 10-Feb-2011

BIONOMICS NOW FEBRUARY 2011 NEWSLETTER 10-Feb-2011

PATENT APPLICATIONS FILED ON COMPOUNDS TO TREAT MEMORY LOSS 04-Feb-2011

OPEN BRIEFING - CEO ON BNC CLINICAL TRIALS AND CASH POSITION 01-Feb-2011

CEO UPDATE AND US INVESTOR PRESENTATION 10-Jan-2011

BIONOMICS NOW DECEMBER 2010 NEWSLETTER 17-Dec-2010

DIRECTORS' AND EXECUTIVE MANAGEMENT SHARE TRADING POLICY 07-Dec-2010

BIONOMICS APPOINTS CORPORATE ADVISER 26-Nov-2010

OPEN BRIEFING - CEO ON COMPANY UPDATE AND BNC210 RESULTS 25-Nov-2010

LATEST BNC210 ANXIETY DRUG DATA TO BE PRESENTED AT US NEUROSCIENCE CONFERENCE 15-Nov-2010

2010 NEUROSCIENCE CONFERENCE POSTER 15-Nov-2010

INVITATION TO TENDER FOR THE PURCHASE OF BIONOMICS SHARES 11-Nov-2010

BIONOMICS’ CEO & MANAGING DIRECTOR EXTENDS CONTRACT 18-Oct-2010

AGM CHAIRMAN & CEO ADDRESSES - 2010 15-Oct-2010

ANNUAL GENERAL MEETING 2010 RESULTS 15-Oct-2010

BIONOMICS BROADCAST - CEO ON GRANTED BNC210 EUROPEAN TRIALS 11-Oct-2010

BNC210 - EUROPEAN APPROVAL GRANTED FOR TWO PHASE IB TRIALS 05-Oct-2010

BIONOMICS 2010 ANNUAL REPORT AND NOTICE OF MEETING 14-Sep-2010

OPEN BRIEFING - BNO CEO ON BNC210 CLINICAL TRIALS 02-Sep-2010

BNC210 DATA PRESENTED AT LEADING EUROPEAN FORUM 30-Aug-2010

2010 STATUTORY ACCOUNTS 19-Aug-2010

BIONOMICS NOW JULY NEWSLETTER 13-Jul-2010

ANTI-ANXIETY COMPOUND BNC210 PHASE I TRIAL SUCCESSFUL: ESTABLISHES FOUR-FOLD INCREASE IN BLOOD DRUG LEVELS FOLLOWING FOOD INTAKE 21-Jun-2010

BIONOMICS PRESENTS BNC105 CLINICAL DATA AT ASCO 07-Jun-2010

OPEN BRIEFING - CEO ON MERCK SERONO EXTENSION 25-May-2010

MERCK SERONO EXTENDS RESEARCH TERM AND FUNDING FOR MULTIPLE SCLEROSIS PROJECT WITH BIONOMICS 24-May-2010

BIONOMICS LIMITED BROADCAST 13-May-2010

SECOND BNC210 PHASE I CLINICAL TRIAL COMMENCES 06-May-2010

NEW BNC105 DATA PRESENTED AT PREMIER INTERNATIONAL CANCER CONFERENCE 16-Apr-2010

OPEN BRIEFING - CEO ON CLINICAL TRIALS UPDATE 31-Mar-2010

BNC105 PHASE II MESOTHELIOMA CLINICAL TRIAL STARTS 26-Mar-2010

BIONOMICS NOW NEWSLETTER - MARCH 2010 16-Mar-2010

BNC210 CLINICAL TRIAL RESULTS CONFIRM SAFETY AND INDICATE REDUCED STRESS HORMONE LEVELS 02-Mar-2010

HALF YEARLY REPORT AND ACCOUNTS 18-Feb-2010

US INVESTOR PRESENTATION 09-Feb-2010

BIONOMICS LIMITED BROADCAST 04-Feb-2010

POSITIVE NEW BNC210 DATA 02-Feb-2010

BNC105 US RENAL CANCER TRIAL INITIATED 27-Jan-2010

OPEN BRIEFING - BNC105 PHASE II TRIAL FOR MESOTHELIOMA 22-Dec-2009

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY 18-Dec-2009

BNO NOW DECEMBER 09 NEWSLETTER 14-Dec-2009

BIONOMICS TO CONDUCT BNC105 PHASE II TRIAL FOR MESOTHELIOMA TREATMENT 09-Dec-2009

BIONOMICS PARTNERS WITH THE AUSTRALASIAN LUNG CANCER TRIALS GROUP AND NHMRC CLINICAL TRIALS CENTRE TO CONDUCT BNC105 PHASE II TRIAL FOR MESOTHELIOMA T 09-Dec-2009

BIONOMICS 2009 AGM BROADCAST 06-Nov-2009

CHAIRMAN'S ADDRESS 04-Nov-2009

CEO'S ADDRESS 04-Nov-2009

NEW CHAIRMAN'S ADDRESS 04-Nov-2009

FIRST STAGE OF BNC210 CLINICAL TRIAL SUCCESSFULLY COMPLETED 27-Oct-2009

LATEST BNC210 DATA TO BE PRESENTED IN US 16-Oct-2009

SPP CLOSES OVERSUBSCRIBED 08-Oct-2009

INVITATION TO SHAREHOLDERS TO TOUR BIONOMICS FACILITY 08-Oct-2009

NOTICE OF ANNUAL GENERAL MEETING /PROXY FORM 02-Oct-2009

ANNUAL REPORT TO SHAREHOLDERS 2009 30-Sep-2009

BOARDROOM RADIO BROADCAST - BNO INVESTOR UPDATE SEPTEMBER 2009 18-Sep-2009

CEO OPEN BRIEFING 17-Sep-2009

2009 SHARE PURCHASE PLAN OFFER - ADDENDUM 17-Sep-2009

CAPITAL RAISING UPDATE - SHARE PURCHASE PLAN 11-Sep-2009

NOTICE OF EXTRAORDINARY GENERAL MEETING & PROXY FORM 10-Sep-2009

$15 MILLION CAPITAL RAISING 08-Sep-2009

INVESTOR UPDATE - SEPTEMBER 2009 08-Sep-2009

START-UP PLACEMENT 03-Sep-2009

APPENDIX 4E 28-Aug-2009

BNO JULY 2009 NEWSLETTER 27-Jul-2009

BIONOMICS TO UNDERTAKE US CLINICAL TRIAL OF BNC105 IN RENAL CELL CANCER 02-Jul-2009

OPEN BRIEFING - BNO CEO ON MILESTONES ACHIEVED 02-Jul-2009

BNO BROADCAST – HEALTHY INVESTMENT eCONFERENCE PRESENTATION 01-Jul-2009

PHASE I CLINICAL TRIAL OF BIONOMICS’ ANTI ANXIETY DRUG BNC210 INITIATED 25-Jun-2009

CANCER FIGHTING COMPOUND - BNC105 TO AIR ON ABC RADIO AUSTRALIA 15-Jun-2009

BOARDROOM RADIO BROADCAST - BNC210 APPROVED TO ENTER TRIAL 04-Jun-2009

INITIAL DATA FROM BNC105 PHASE I CLINICAL TRIAL PRESENTED 29-May-2009

OEN BRIEFING BNC105 INTERIM DATA 29-May-2009

BIONOMICS’ ANXIETY DRUG CANDIDATE APPROVED TO ENTER HUMAN CLINICAL TRIAL 21-May-2009

BNO - CEO PRESENTATION MAY 2009 05-May-2009

NEW BNC105 DATA PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE 22-Apr-2009

OPEN BRIEFING - NEW DATA ON BNC105 22-Apr-2009

BIONOMICS NAMED IN SMART 100 INDEX 15-Apr-2009

BIONOMICS APRIL 2009 NEWSLETTER 09-Apr-2009

BOARDROOM RADIO BROADCAST - HALF YEARLY REPORT 03-Mar-2009

KEY INSTITUTIONAL INVESTOR SUPPORTS BNO CAPITAL RAISING 10-Feb-2009

OPEN BRIEFING - CEO ON OPTION EXPIRY 05-Feb-2009

BNOOB OPTIONS EXERCISE 30-Jan-2009

INVESTOR PRESENTATION - JANUARY 2009 19-Jan-2009

OPEN BRIEFING - CEO UPDATE 15-Jan-2009

BIONOMICS NOW JANUARY NEWSLETTER 14-Jan-2009

BIONOMICS ANNOUNCES ADDITION TO BOARD 23-Dec-2008

BNOOB OPTIONS REMINDER 22-Dec-2008

BIONOMICS’ ANTI-ANXIETY CANDIDATE BNC210 SUCCESSFULLY COMPLETES SAFETY STUDIES 17-Dec-2008

OPTIONS UNDERWRITING 16-Dec-2008

OPEN BRIEFING - BNO CEO ON RECENT DEVELOPMENTS 12-Nov-2008

AGM BROADCAST 11-Nov-2008

AUSTIN HEALTH COMES ON BOARD BNC105 TRIAL 05-Nov-2008

BNC105 CLINICAL TRIAL UPDATE 16-Sep-2008

US AND EUROPEAN INVESTOR PRESENTATION 08-Sep-2008

BIONOMICS NOW SEPTEMBER NEWSLETTER 05-Sep-2008

BIONOMICS’ COMPOUND BNC210 DECREASES ANXIETY IN ANIMAL MODELS - LATEST DATA PRESENTED AT EUROPEAN CONFERENCE 01-Sep-2008

BIONOMICS' 2007/2008 PRELIMINARY FINAL RESULTS 22-Aug-2008

BIONOMICS EXTENDS CONTRACT OF CEO AND MANAGING DIRECTOR DEBORAH RATHJEN 08-Aug-2008

BNO AUDIO BROADCAST 17-Jul-2008

BIONOMICS COMPLETES GMP SYNTHESIS OF ANTI-ANXIETY DRUG BNC210 09-Jul-2008

BNO NEWSLETTER JULY 2008 30-Jun-2008

OPEN BRIEFING - BNO & MERCK SERONO DEVELOPMENT AGREEMENT 24-Jun-2008

MERCK SERONO AND BIONOMICS ANNOUNCE MULTIPLE SCLEROSIS DEVELOPMENT AND LICENSING AGREEMENT 19-Jun-2008

BNC105 NAMED AS ONE OF THE “TOP FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS” IN THOMSON PHARMA THE ONES TO WATCH REVIEW 03-Jun-2008

BIONOMICS AWARDS GMP MANUFACTURE CONTRACT FOR ANXIETY DRUG CANDIDATE BNC210 16-Apr-2008

BIONOMICS PRESENTS BNC105 DATA AT INTERNATIONAL CANCER CONFERENCE 14-Apr-2008

BNO NEWSLETTER APRIL 2008 02-Apr-2008

BIONOMICS ADVANCES ANTI-ANXIETY CANDIDATE BNC210 11-Mar-2008

BIONOMICS STRENGTHENS BOARD WITH NEW APPOINTMENT 28-Feb-2008

CEO ON BNC105 PHASE I CLINICAL TRIALS 27-Feb-2008

TREATMENT OF FIRST PATIENT IN PHASE I CLINICAL TRIAL OF BIONOMICS’ ANTI-CANCER DRUG BNC105 26-Feb-2008

BIONOMICS ACHIEVES US$1 MILLION MILESTONE PAYMENT FROM GENMAB 19-Feb-2008

BIONOMICS NOW NEWSLETTER 21-Jan-2008

BIONOMICS’ ANTI-CANCER COMPOUND GAINS IND APPROVAL 22-Nov-2007

CHAIRMAN AND CEO ADDRESS 07-Nov-2007

BIONOMICS ACHIEVES KEY MILESTONES 07-Nov-2007

OPEN BRIEFING - CEO ON PIPELINE DEVELOPMENT STATUS 07-Nov-2007

AGM BROADCAST 07-Nov-2007

LATEST DATA PRESENTED AT INTERNATIONAL CONFERENCE 05-Oct-2007

NEWSLETTER TO SHAREHOLDERS 14-Sep-2007

2006 / 2007 FINANCIAL RESULTS – VARIATION TO 4E 07-Sep-2007

BIONOMICS' 2006/2007 PRELIMINARY FINAL RESULTS 29-Aug-2007

BIONOMICS TO DEVELOP CANCER DRUG TARGET BNO69 WITH SUPPORT FROM THE CANCER THERAPEUTICS CRC 06-Aug-2007

IBRO 2007 CONFERENCE POSTER - BNC210 13-Jul-2007

IBRO 2007 CONFERENCE POSTER - Kv1.3 ION CHANNEL BLOCKERS 13-Jul-2007

BIONOMICS PRESENTS MULTIPLE SCLEROSIS AND ANXIETY DRUG DATA AT INTERNATIONAL CONFERENCE 13-Jul-2007

S708A PLACEMENT NOTICE 05-Jul-2007

BNOOA OPTION EXPIRY NOTICE 03-Jul-2007

AUDIO BROADCAST - BIONOMICS RAISES $10 MILLION IN PRIVATE PLACEMENT 21-Jun-2007

BIONOMICS RAISES $10 MILLION IN PRIVATE PLACEMENT 20-Jun-2007

BIONOMICS NEWSLETTER - JUNE 2007 12-Jun-2007

BIONOMICS’ VALIDATES THIRD CANCER APPLICATION FOR ANTI-CANCER COMPOUND BNC105 04-Jun-2007

OPEN BRIEFING - BIONOMICS PIPELINE UPDATE 04-Jun-2007

AUDIO BROADCAST - BIONOMICS MD - NEW DRUG CANDIDATE FOR ANXIETY 31-May-2007

BIONOMICS VALIDATES DRUG CANDIDATE FOR ANXIETY 29-May-2007

BIONOMICS COMPLETES GMP SYNTHESIS OF CANCER DRUG BNC105 ON TIME AND ON BUDGET 23-Apr-2007

OPEN BRIEFING - UPDATE ON BNC105 MILESTONES 23-Apr-2007

US$890 MILLION VDA DEAL INDICATES VALUE OF BIONOMICS’ BNC105 CANCER COMPOUND 23-Apr-2007

BIONOMICS ESTABLISHES NEW LABORATORY FACILITY TO ACCELERATE LATER STAGE DRUG DEVELOPMENT 19-Apr-2007

BIONOMICS PRESENTS CANCER DATA AT AACR CONFERENCE 17-Apr-2007

AACR Poster 17-Apr-2007

INVESTOR BRIEFING - EXCELLENCE IN BIOTECHNOLOGY & INVESTMENT CONFERENCE, SYDNEY 20-Mar-2007

M & A PRESENTATION – EXCELLENCE IN BIOTECHNOLOGY & INVESTMENT CONFERENCE, SYDNEY 20-Mar-2007

BIONOMICS SHAREHOLDER NEWSLETTER – MARCH 2007 13-Mar-2007

BIONOMICS TAKES KEY STEP FORWARD IN THE DEVELOPMENT OF ANTI-CANCER DRUG BNC105 21-Feb-2007

BIONOMICS MEETS WITH FDA IN US 17-Jan-2007

BIONOMICS TO BENEFIT FROM AU$37.60M FEDERAL CRC GRANT FOR CANCER DRUG DEVELOPMENT 02-Jan-2007

BIONOMICS NEWSLETTER 04-Dec-2006

BIONOMICS MD UPDATES OUTLOOK 16-Nov-2006

BIONOMICS DELIVERS ON MILESTONES FOR DRUG DISCOVERY PROGRAMS 09-Nov-2006

AGM CHAIRMAN AND CEO ADDRESSES 2006 09-Nov-2006

BNO AUDIO BROADCAST 09-Nov-2006

BNO AUDIO BROADCAST 25-Oct-2006

BIONOMICS AND SAFC PHARMA SIGN CONTRACT TO MANUFACTURE BNC105 25-Oct-2006

ASIA PACIFIC LIFE SCIENCES FORUM - PRESENTATION 12-Oct-2006